All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual abstract | Enasidenib as monotherapy and in combination with azacitidine for patients with IDH2-mutated MDS: results from a phase II study

Oct 14, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelodysplastic syndromes.

The MDS Hub is pleased to present a visual abstract representing key data from a phase II clinical trial (NCT03383575) evaluating enasidenib, both in combination with azacitidine and as monotherapy in patients with high-risk IDH2-mutated MDS. The safety and efficacy of enasidenib has been previously reported by the MDS Hub.

Visual Abstract

To download this visual abstract, click below.

Download here

Your opinion matters

Which is a global phase III trial for MDS that utilizes a biomarker for patient selection? ENHANCE (magrolimab), SELECT-MDS-1 (tamibarotene), VERONA (venetoclax), or STIMILUS-MDS3 (sabatolimab)?
0 votes - 10 days left ...


Subscribe to get the best content related to MDS delivered to your inbox